Better Therapeutics to Host Conference Call to Review Results from Pivotal Clinical Trial of BT-001 for Type 2 Diabetes
July 26 2022 - 7:30AM
Business Wire
Conference call and webcast on Thursday, July
28, 2022, at 8:30 a.m. ET
Better Therapeutics, Inc. (NASDAQ:
BTTX), a prescription digital therapeutics (PDT) company developing
nutritional cognitive behavioral therapy (nCBT) to address the root
causes of cardiometabolic diseases, today announced it will host a
conference call and webcast on Thursday, July 28, 2022, at 8:30
a.m. ET to review the results from the pivotal clinical trial of
BT-001 after 180 days of treatment for type 2 diabetes. Members of
the Better Therapeutics management team will be joined by Marc
Bonaca, MD, MPH, Professor of Medicine and Director of Vascular
Research at University of Colorado.
The live conference call may be accessed by dialing (800)
715-9871 (domestic) or (646) 307-1963 (international) and referring
to conference ID: 4326594. All participants are encouraged to
dial-in 10 minutes prior to the start time. The live webcast may be
accessed by visiting the event page here. A replay of the webcast
may be accessed from the Presentations & Events page in the
Investors section of the Better Therapeutics corporate website:
www.bettertx.com.
About Better Therapeutics
Better Therapeutics is a prescription digital therapeutics (PDT)
company developing a novel form of cognitive behavioral therapy to
address the root causes of cardiometabolic diseases. The company
has developed a proprietary platform for the development of
FDA-regulated, software-based solutions for type 2 diabetes, heart
disease and other conditions. The cognitive behavioral therapy
delivered by Better Therapeutics’ PDT is designed to enable changes
in neural pathways of the brain so lasting changes in behavior
become possible. Addressing the underlying causes of these diseases
has the potential to dramatically improve patient health while
lowering healthcare costs. Better Therapeutics clinically validated
mobile applications are intended to be prescribed by physicians and
reimbursed like traditional medicines.
For more information visit: bettertx.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220726005151/en/
Investor Relations: Mark Heinen IR@bettertx.com
Media: Ryan McKenna at Real Chemistry
rmckenna@realchemistry.com
Better Therapeutics (NASDAQ:BTTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Better Therapeutics (NASDAQ:BTTX)
Historical Stock Chart
From Apr 2023 to Apr 2024
